Apogee Therapeutics Reports Positive Phase 1b Data for Zumilokibart in Asthma, Plans Phase 3 Trial in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Should l Buy APGE?
Source: NASDAQ.COM
- Clinical Trial Progress: Apogee Therapeutics reported rapid and durable suppression of fractional exhaled nitric oxide in all patients during the Phase 1b trial of zumilokibart, with effects maintained through 32 weeks in some, indicating strong potential for treating mild-to-moderate asthma.
- Future Data Releases: The company expects to release Phase 2 APEX Part A maintenance data in Q1 2026, followed by induction data from Part B in Q2 2026, which will provide critical insights for further drug development.
- New Trial Plans: Apogee plans to initiate a Phase 3 trial for atopic dermatitis in the second half of 2026, aiming for a potential launch in 2029, demonstrating the company's intent to expand into dermatological treatments, which could open new revenue streams.
- Strong Financial Position: As of September 30, 2025, Apogee had $913 million in cash reserves, ensuring a runway into the second half of 2028, providing robust support for future R&D and market initiatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APGE
Wall Street analysts forecast APGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APGE is 102.50 USD with a low forecast of 70.00 USD and a high forecast of 137.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 62.130
Low
70.00
Averages
102.50
High
137.00
Current: 62.130
Low
70.00
Averages
102.50
High
137.00
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Apogee Therapeutics (APGE) Options Volume Surges 46.6% Today
- Active Options Trading: Apogee Therapeutics has seen an options volume of 4,166 contracts today, equating to approximately 416,600 shares, indicating a trading activity level of 46.6% of its average daily volume over the past month.
- High Demand Options: Notably, the $90 strike call option expiring on March 20, 2026, has seen a significant volume of 2,505 contracts traded today, representing about 250,500 shares, reflecting strong market interest at this strike price.
- Ceva Inc Options Activity: Concurrently, Ceva Inc has recorded an options volume of 1,294 contracts today, approximately 129,400 shares, which corresponds to 45.8% of its average daily trading volume over the past month.
- Increased Interest in Strike Price: Among Ceva's options, the $30 strike call option expiring on February 20, 2026, has seen a trading volume of 506 contracts today, representing around 50,600 shares, indicating a rising market focus on this strike price.
See More
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
See More
Apogee Therapeutics CMO Sells $1.46 Million in Shares
- Share Sale: Carl Dambkowski, CMO of Apogee Therapeutics, sold 18,700 shares for approximately $1.46 million, reducing his direct holdings by 8.09% from 231,223 to 212,523 shares, indicating a structured liquidity management approach.
- Option Exercise: Prior to the sale, Dambkowski exercised 14,025 stock options, maintaining a substantial stake worth about $16.8 million, which reflects his ongoing confidence in the company's future prospects.
- Market Performance: Apogee Therapeutics shares have surged approximately 60% over the past year, significantly outperforming the S&P 500's 18% gain, indicating growing market confidence in its immunology pipeline and competitive positioning in the biotech sector.
- Financial Position: As of the third quarter, Apogee reported $913 million in cash and cash equivalents, ensuring funding through the second half of 2028, which supports its strategic development in clinical-stage biologics.
See More
Apogee Therapeutics CMO Sells $1.46 Million in Shares Following Options Exercise
- Significant Transaction Size: Apogee Therapeutics' CMO Carl Dambkowski sold 18,700 shares for a total value of $1.46 million on Wednesday, which is substantially larger than his recent median sale size of 3,690 shares, highlighting the impact of the options exercise on transaction scale.
- Options Exercise and Sale: The transaction involved exercising 14,025 options and immediately selling 18,700 shares, indicating a structured liquidity event following a strong market performance rather than a signal of clinical confidence in the company.
- Stable Equity Holdings: Post-transaction, Dambkowski retains 212,523 shares valued at approximately $16.8 million, demonstrating continued confidence in the company despite the large sale.
- Company Financial Health: Apogee Therapeutics has a market capitalization of $5.3 billion and a 60% stock price increase over the past year, reflecting strong market confidence in its immunology pipeline, while closing the third quarter with $913 million in cash and equivalents, ensuring funding for future needs.
See More
Apogee Therapeutics CMO Sells 10,900 Shares for $817,500
- Significant Transaction Size: Apogee Therapeutics' Chief Medical Officer Carl Dambkowski executed an open-market sale of 10,900 shares for approximately $817,500 on December 4, 2025, marking the largest single transaction in the past 12 months, indicating a potential shift in confidence regarding the company's stock.
- Ownership Impact: This sale accounted for 3.87% of Dambkowski's direct holdings, significantly higher than the median 1.13% impact over the past year, suggesting an acceleration in his selling activity, which may reflect adjustments in expectations for future market conditions.
- Declining Holdings Trend: Dambkowski's direct ownership has decreased from 331,948 shares at the beginning of 2025 to 271,108 shares post-transaction, representing an 18.33% reduction, indicating a possible waning confidence in the company's future prospects.
- Positive Market Reaction: Although this transaction occurred against the backdrop of Apogee's stock surging over 45% by the end of 2025, Dambkowski's sale was part of a prearranged trading plan designed to mitigate insider trading risks, demonstrating his ongoing commitment to the company's future growth.
See More
APGE Options Offer 9.33% Yield Boost on $75 Put Contract
- Attractive Options: The $75 put option for APGE has a current bid of $7.00, and if an investor sells-to-open this contract, their effective purchase price drops to $68.00, representing a 3% discount compared to the current stock price of $77.68, making it appealing for potential buyers.
- Yield Potential: Should the put contract expire worthless, it would yield a 9.33% return on cash commitment, equating to an annualized yield of 47.34%, highlighting the contract's attractiveness in the current market context.
- Market Volatility: The implied volatility for the put contract stands at 77%, while the call contract's implied volatility is at 80%, indicating market expectations for price fluctuations in APGE stock, which investors should monitor for strategic decision-making.
- Covered Call Strategy: The $80 call option for APGE has a current bid of $7.30, and if investors buy shares at the current price and sell this call, they could achieve a total return of 12.38% if the stock is called away at expiration, enhancing overall investment returns.
See More
Apogee Therapeutics (APGE) Options Volume Surges 46.6% Today
- Active Options Trading: Apogee Therapeutics has seen an options volume of 4,166 contracts today, equating to approximately 416,600 shares, indicating a trading activity level of 46.6% of its average daily volume over the past month.
- High Demand Options: Notably, the $90 strike call option expiring on March 20, 2026, has seen a significant volume of 2,505 contracts traded today, representing about 250,500 shares, reflecting strong market interest at this strike price.
- Ceva Inc Options Activity: Concurrently, Ceva Inc has recorded an options volume of 1,294 contracts today, approximately 129,400 shares, which corresponds to 45.8% of its average daily trading volume over the past month.
- Increased Interest in Strike Price: Among Ceva's options, the $30 strike call option expiring on February 20, 2026, has seen a trading volume of 506 contracts today, representing around 50,600 shares, indicating a rising market focus on this strike price.
See More
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
See More
Apogee Therapeutics CMO Sells $1.46 Million in Shares
- Share Sale: Carl Dambkowski, CMO of Apogee Therapeutics, sold 18,700 shares for approximately $1.46 million, reducing his direct holdings by 8.09% from 231,223 to 212,523 shares, indicating a structured liquidity management approach.
- Option Exercise: Prior to the sale, Dambkowski exercised 14,025 stock options, maintaining a substantial stake worth about $16.8 million, which reflects his ongoing confidence in the company's future prospects.
- Market Performance: Apogee Therapeutics shares have surged approximately 60% over the past year, significantly outperforming the S&P 500's 18% gain, indicating growing market confidence in its immunology pipeline and competitive positioning in the biotech sector.
- Financial Position: As of the third quarter, Apogee reported $913 million in cash and cash equivalents, ensuring funding through the second half of 2028, which supports its strategic development in clinical-stage biologics.
See More
Apogee Therapeutics CMO Sells $1.46 Million in Shares Following Options Exercise
- Significant Transaction Size: Apogee Therapeutics' CMO Carl Dambkowski sold 18,700 shares for a total value of $1.46 million on Wednesday, which is substantially larger than his recent median sale size of 3,690 shares, highlighting the impact of the options exercise on transaction scale.
- Options Exercise and Sale: The transaction involved exercising 14,025 options and immediately selling 18,700 shares, indicating a structured liquidity event following a strong market performance rather than a signal of clinical confidence in the company.
- Stable Equity Holdings: Post-transaction, Dambkowski retains 212,523 shares valued at approximately $16.8 million, demonstrating continued confidence in the company despite the large sale.
- Company Financial Health: Apogee Therapeutics has a market capitalization of $5.3 billion and a 60% stock price increase over the past year, reflecting strong market confidence in its immunology pipeline, while closing the third quarter with $913 million in cash and equivalents, ensuring funding for future needs.
See More
Apogee Therapeutics CMO Sells 10,900 Shares for $817,500
- Significant Transaction Size: Apogee Therapeutics' Chief Medical Officer Carl Dambkowski executed an open-market sale of 10,900 shares for approximately $817,500 on December 4, 2025, marking the largest single transaction in the past 12 months, indicating a potential shift in confidence regarding the company's stock.
- Ownership Impact: This sale accounted for 3.87% of Dambkowski's direct holdings, significantly higher than the median 1.13% impact over the past year, suggesting an acceleration in his selling activity, which may reflect adjustments in expectations for future market conditions.
- Declining Holdings Trend: Dambkowski's direct ownership has decreased from 331,948 shares at the beginning of 2025 to 271,108 shares post-transaction, representing an 18.33% reduction, indicating a possible waning confidence in the company's future prospects.
- Positive Market Reaction: Although this transaction occurred against the backdrop of Apogee's stock surging over 45% by the end of 2025, Dambkowski's sale was part of a prearranged trading plan designed to mitigate insider trading risks, demonstrating his ongoing commitment to the company's future growth.
See More
APGE Options Offer 9.33% Yield Boost on $75 Put Contract
- Attractive Options: The $75 put option for APGE has a current bid of $7.00, and if an investor sells-to-open this contract, their effective purchase price drops to $68.00, representing a 3% discount compared to the current stock price of $77.68, making it appealing for potential buyers.
- Yield Potential: Should the put contract expire worthless, it would yield a 9.33% return on cash commitment, equating to an annualized yield of 47.34%, highlighting the contract's attractiveness in the current market context.
- Market Volatility: The implied volatility for the put contract stands at 77%, while the call contract's implied volatility is at 80%, indicating market expectations for price fluctuations in APGE stock, which investors should monitor for strategic decision-making.
- Covered Call Strategy: The $80 call option for APGE has a current bid of $7.30, and if investors buy shares at the current price and sell this call, they could achieve a total return of 12.38% if the stock is called away at expiration, enhancing overall investment returns.
See More
